B2B Payment Solutions Ltd Secures FCA AEMI Approval to Offer e-Payment Services in UK and Europe
9.9.2020 12:00:00 EEST | Business Wire | Press release
B2B Payment Solutions Ltd, part of the B2Broker Group of companies, is pleased to announce that the United Kingdom’s Financial Conduct Authority (FCA) has granted the company an Electronic Money Institution License (AEMI). The licence permits companies to engage in e-money related and payment services in the UK and European Economic Area (EEA).
As a regulated AEMI e-money provider, B2B Payment Solutions Ltd will now be able to act as a payment intermediary. The company’s primary focus is to offer payment services to regulated Forex brokers and licensed liquidity providers as well as corporate IT businesses and e-commerce companies, and create a bespoke ecosystem where brokers will be able to deposit and withdraw funds to and from margin accounts and their end-users across Europe and the UK.
The company will therefore offer digital banking services that are ideally geared up for the regulated brokerage industry. According to company estimations, there are over 1,000 regulated brokers and liquidity providers with hundreds of thousands of end users, all of whom will be able to deposit and withdraw in just seconds. In this respect, B2B Payment Solutions Ltd will offer sub IBANs, SEPA transfers and Faster Payments.
Future plans include the addition of further services including SWIFT transfers, card processing and electronic money wallets. The company also intends to start offering the same services to other types of regulated financial institutions who possess PI, API, EMI and AEMI licenses.
Ievgen Iugrinov, the company's Product Manager commented, “Our goal is to enable the B2Broker ecosystem to access payment accounts and attract new clients to the financial industry. We are delighted to be able to offer the latest genre of e-payment services as an AEMI which places us in the same league as leading industry players who also conduct their UK and European operations under the same licence.”
Securing an AEMI licence is a key part of the company's strategy to expand its products globally and extend its services and offer better and more competitive products to its customers across the UK and Europe.
Established in 2020, B2B Payment Solutions Ltd (ref no: 901100) is a financial technology company headquartered in London, UK offering a range of digital banking and payment services.
These include worldwide money transfers, issuing e-wallets and prepaid cards, setting up direct debits, processing standing orders, BACS/CHAPS payments and mobile payment transactions. All payments are easy and secure, and using algorithms which trigger fraud, money laundering and other illicit activities.
Evgeniya Mykulyak, Co-Founder at B2B Payment Solutions Ltd added, “I believe we will offer a groundbreaking service to all users who need instant access to a range of e-payment services. We will be providing a range of services where our customers can be assured that their transactions will not only be fast, but safe and secure. With deep industry knowledge in the payments industry, our company has big plans for the future which will firmly place us in a prime position in the Fintech industry.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005413/en/
Contact information
Rosemary Barnes
Head of PR & Marketing
pr@b2broker.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom